West Pharmaceutical Services (WST) to Release Quarterly Earnings on Thursday

Key Points

• West Pharmaceutical Services (NYSE: WST) is set to release its Q3 2025 earnings on October 23rd, with analysts predicting earnings of $1.67 per share and revenue of $788.415 million.
• The company recently increased its quarterly dividend to $0.22 per share, up from $0.21, reflecting a positive financial trajectory and a low dividend payout ratio of 12.57%.
• West Pharmaceutical's stock has a market cap of $18.93 billion and remains a popular choice among analysts, showing strong support with a consensus price target of $321.89.

West Pharmaceutical Services (NYSE:WST - Get Free Report) is anticipated to release its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect West Pharmaceutical Services to post earnings of $1.67 per share and revenue of $788.4150 million for the quarter. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS.Parties are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.33. The firm had revenue of $766.50 million during the quarter, compared to the consensus estimate of $725.11 million. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The firm's revenue for the quarter was up 9.2% on a year-over-year basis. During the same period last year, the firm posted $1.52 EPS. On average, analysts expect West Pharmaceutical Services to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $263.18 on Thursday. West Pharmaceutical Services has a 12-month low of $187.43 and a 12-month high of $352.33. The stock has a market cap of $18.93 billion, a P/E ratio of 39.40, a PEG ratio of 4.64 and a beta of 1.07. The company has a current ratio of 2.78, a quick ratio of 2.08 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average of $253.84 and a two-hundred day moving average of $230.72.

West Pharmaceutical Services Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 19th. Shareholders of record on Wednesday, November 12th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, November 12th. This is a positive change from West Pharmaceutical Services's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 0.3%. West Pharmaceutical Services's dividend payout ratio (DPR) is 12.57%.

Analyst Upgrades and Downgrades

WST has been the topic of a number of analyst reports. Barclays increased their price objective on West Pharmaceutical Services from $260.00 to $275.00 and gave the company an "equal weight" rating in a research note on Thursday, October 2nd. Evercore ISI set a $350.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, October 7th. Wall Street Zen raised shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Zacks Research lowered shares of West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 23rd. Finally, Rothschild & Co Redburn initiated coverage on shares of West Pharmaceutical Services in a research note on Monday, September 15th. They issued a "buy" rating and a $311.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $321.89.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of large investors have recently modified their holdings of WST. CYBER HORNET ETFs LLC purchased a new position in West Pharmaceutical Services in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $47,000. State of Wyoming bought a new position in West Pharmaceutical Services during the 2nd quarter valued at $49,000. Darwin Wealth Management LLC acquired a new position in West Pharmaceutical Services in the second quarter worth about $75,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier's stock worth $98,000 after acquiring an additional 197 shares in the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.